SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that its Board of Directors has authorized the company to purchase up to $1 billion of United Therapeutics’ common stock. This program builds on United Therapeutics’ planned $400 million paydown of its revolving credit facility in 2024, of which $100 million was paid down during the first quarter of 2024. To enact the program, United T
Business Wire Stock Sale/Buyback News
